Vumerity™ (diroximel fumarate) – New drug approval
October 30, 2019 - Biogen and Alkermes announced the FDA approval of Vumerity (diroximel fumarate), for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Top